Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.
Cindy Neuzillet , Andrea Casadei Gardini , Bertrand Brieau , Caterina Vivaldi
European Journal of Cancer 111 94 -106
11
2019
Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study
Simon Pernot , Olivier Dubreuil , Thomas Aparicio , Karine Le Malicot
British Journal of Cancer 119 ( 4) 424 -428
12
2018
Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study.
Geraldine Perkins , Magali Svrcek , Cecile Bouchet-Doumenq , Thibault Voron
British Journal of Cancer 120 ( 7) 697 -702
6
2019
Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.
Thomas Aparicio , , Jaafar Bennouna , Karine Le Malicot
British Journal of Cancer 122 ( 7) 957 -962
3
2020
C-MET expression as an independent prognostic marker in resected pancreatic ductal adenocarcinoma (PDAC): Proposition of a novel reliable immunostaining scoring method.
Cindy Neuzillet , Jerome Cros , Annemilai Tijeras-Raballand , Louis de Mestier
Journal of Clinical Oncology 32
1
2014
CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Mathilde Wagner , Celia Antunes , Daniel Pietrasz , Christophe Cassinotto
European Radiology 27 ( 7) 3104 -3116
58
2017
Trastuzumab Re-Introduction with FOLFIRI for Treatment of HER2 Overexpression-Advanced Gastric Adenocarcinoma Following Failure of Other Trastuzumab-Based Chemotherapy Regimens
Olivier Dubreuil , Aziz Zaanan , Olivier Pellerin , Jean-Baptiste Bachet
Case Reports in Clinical Medicine 04 ( 4) 131 -136
1
2015
Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'
Simon Pernot , Jean-Baptiste Bachet , Alix Portal , Julien Taieb
British Journal of Cancer 114 ( 11)
3
2016
Practical considerations in the use of regorafenib in metastatic colorectal cancer.
Fotios Loupakis , Lorenzo Antonuzzo , Jean-Baptiste Bachet , Feng-Che Kuan
Therapeutic Advances in Medical Oncology 12 1758835920956862 -1758835920956862
2020
RAS mutations concordance in circulating tumor DNA (ctDNA) and tissue in metastatic colorectal cancer (mCRC): RASANC, an AGEO prospective multicenter study.
Jean-Baptiste Bachet , Olivier Bouche , Julien Taïeb , Olivier Dubreuil
Journal of Clinical Oncology 35 11509 -11509
5
2017
Colorectal cancer (CRC) patients surveyed by 18FDGPET-CT (PET-CT): An open-label multicenter randomized trial (NCT 00624260).
Iradj Sobhani , Isabelle Baumgaertner , Emmanuel Itti , Alain Luciani
Journal of Clinical Oncology 35 ( 15_suppl) 3520 -3520
3
2017
Clinical and molecular characterization of patients with metastatic colorectal cancer harbouring DNA mismatch repair deficiency.
Romain Cohen , Elisabeth Hain , Pascale Cervera , Olivier Buhard
Journal of Clinical Oncology 35 ( 15_suppl) 3563 -3563
2017
Echocardiographic Follow-Up of Treated Patients With Carcinoid Syndrome
Nicolas Mansencal , Emmanuel Mitry , Jean-Baptiste Bachet , Philippe Rougier
The American Journal of Cardiology 105 ( 11) 1588 -1591
20
2010
Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study.
Julien Taieb , Timothy Jay Price , Fortunato Ciardiello , Marc Peeters
Journal of Clinical Oncology 37 638 -638
2
2019
Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review.
Raëf Abdallah , Valérie Taly , Shulin Zhao , Daniel Pietrasz
Cancer Treatment Reviews 87 102028
8
2020
Accumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients treated with regorafenib (REGO).
Benoit Rousseau , Arezki Khaled Boukerma , Julie Henriques , Romain Cohen
Journal of Clinical Oncology 37 3121 -3121
2019
Who can benefit from a liver surgery for metastatic colorectal cancer in the era of modern chemotherapy? A post hoc analysis of the MIROX phase III trial.
Samira Makhloufi , Anthony Turpin , Thierry Andre , Francois-Rene Pruvot
Journal of Clinical Oncology 37 3547 -3547
1
2019
Prognosis and chemosensitivity of non-V600E BRAF mutations in metastatic colorectal carcinoma (mCRC): An AGEO French multicenter retrospective cohort.
Aline Derosiere , Vincent Nicolai , David Malka , Astrid Pozet
Journal of Clinical Oncology 37 3575 -3575
2
2019
Methylated circulating tumor DNA (Met-DNA) as an independent prognostic factor in metastatic pancreatic adenocarcinoma (mPAC) patients.
Daniel Pietrasz , Shufang Wang-Renault , Laetitia Dahan , Julien Taieb
Journal of Clinical Oncology 37 4136 -4136
2
2019
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig , Anne Cayre , Gilles Manceau , Emmanuel Buc
Journal of Clinical Oncology 27 ( 35) 5924 -5930
838
2009